Description of the Transaction and Basis of the Pro Forma Presentation (Details Narrative) - USD ($) |
3 Months Ended | ||
|---|---|---|---|
Mar. 18, 2021 |
Mar. 31, 2021 |
Dec. 31, 2020 |
|
| Common stock, shares issued | 8,326,730 | 8,792,946 | |
| Common stock, shares outstanding | 8,326,730 | 8,792,946 | |
| Pro Forma [Member] | |||
| Common stock, per share | $ 0.7718 | ||
| Equity ownership, percentage | 22.95% | ||
| Common stock, shares outstanding | 40,043,504 | ||
| Stock options, outstanding | |||
| Contribution and assignment agreement, description | The Company entered into a Contribution and Assignment Agreement (the "Contribution and Assignment Agreement") by and among the Company, Cystron Biotech, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Cystron"), and Oravax Medical, Inc. ("Oravax"), pursuant to which the Company agreed to contribute (i) an amount in cash equal to $1,500,000 to Oravax, (ii) cause Cystron to contribute substantially all of the assets associated with its business of developing and manufacturing a COVID-19 Vaccine Candidate to Oravax, and deliver to Premas on behalf of Cystron $1,200,000 in satisfaction of all current accrued and unpaid milestone payments due pursuant to the Amended and Restated License Agreement, dated March 19, 2020, between Cystron and Premas (the "License Agreement," and such transaction, the "Contribution Transaction"). The aggregate purchase price for the contribution consisted of 390,000 shares of capital stock of Oravax, or 13% of the projected outstanding shares of Oravax (the "Oravax Shares") and the assumption of all obligations or liabilities in respect of the assets of Cystron, including the License Agreement. In addition, Oravax agreed to pay future royalties to the Company equal to 2.5% of all net sales of products (or combination products) manufactured, tested, distributed and/or marketed by Oravax or its subsidiaries. In addition to the cash amount equal to $1,200,000, the Company will hold for payment and delivery, an additional amount equal to $300,000 and 67,286 shares of the Company's common stock and 72,922 shares of the Company's Series D Convertible Preferred Stock, due to Premas, to be paid and delivered at a future date upon Premas obtaining the requisite permissions from Indian Authorities and making a demand on the Company for payment and delivery of the same. For the avoidance of doubt, the 134,572 shares of Akers common stock and 72,992 shares of the Company's Series D Convertible Preferred Stock referred to in the preceding sentence were previously issued and are outstanding in the stock books of the Company registered in the name of Premas. | ||
| Pro Forma [Member] | Minimum [Member] | |||
| Transaction costs | $ 750,000 | ||
| Pro Forma [Member] | Maximum [Member] | |||
| Transaction costs | $ 1,500,000 | ||
| Pro Forma [Member] | Supera Merger [Member] | |||
| Equity ownership, percentage | 40.00% | ||
| Reimbursement expenses | $ 444,000 | ||
| Pro Forma [Member] | Starwood Line of Credit Merger [Member] | |||
| Reduction to minimum cash contribution merger | $ 25,000,000 | ||
| Pro Forma [Member] | MyMD Pharmaceuticals, Inc., [Member] | |||
| Equity ownership, percentage | 77.05% | ||
| Number of shares issued, shares | 28,553,307 | ||
| Number of stock options issued | 4,188,315 | ||
| Common stock, shares issued | 73,991,413 | ||
| Common stock, shares outstanding | 73,991,413 | ||
| Stock options, outstanding | 10,853,360 | ||
| Debt instrument, face amount | $ 3,000,000 | ||
| Pro Forma [Member] | MyMD Pharmaceuticals, Inc., [Member] | Supera Share Holder [Member] | |||
| Number of shares issued, shares | 33,937,909 | ||
| Pro Forma [Member] | MyMD Pharmaceuticals, Inc., [Member] | Supera Merger [Member] | |||
| Common stock, per share | $ 1.3575 | ||
| Equity ownership, percentage | 60.00% |